AZD-3783
AZD-3783 is a serotonin 5-HT1B receptor antagonist which was under development for the treatment of major [depressive disorder] and anxiety disorders. It was being developed by AstraZeneca. The drug reached Phases of [clinical research#Phase I|phase 1] clinical trials prior to the discontinuation of its development. It was discontinued following unexpected neurotoxicity findings in animals.